Laidback Al
Well-known member
Recent Approaches in Hantavirus Vaccine Development
Piet Maes; Jan Clement; Marc Van Ranst
Authors and Disclosures
Posted: 02/09/2009; Expert Rev Vaccines. 2009;8(1):67-76. ? 2009 Expert Reviews Ltd.
Abstract
Rodent-borne hantaviruses are associated with two main clinical disorders in humans: hemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome. Although hantavirus diseases can be life threatening and numerous research efforts are focused on the development of hantavirus prevention, no specific antiviral therapy is yet available and, at this time, no WHO-approved vaccine has gained widespread acceptance. This review will summarize the current knowledge and recent progress as well as new speculative approaches in the development of hantavirus vaccines.
. . . .
Until now, there is no WHO-approved hantavirus vaccine available. However, at least three different inactivated vaccines, based on purified suckling-mouse brains, golden hamster kidney cells or Mongolian gerbil kidney cells, were developed in Korea and/or China, and which are being used only locally. A variety of vaccine approaches, however, have been investigated using both inactivated virus and recombinant DNA technology. These approaches will be further discussed later in this review.
http://www.medscape.com/viewarticle/586233
full article requires access to Medscape
Piet Maes; Jan Clement; Marc Van Ranst
Authors and Disclosures
Posted: 02/09/2009; Expert Rev Vaccines. 2009;8(1):67-76. ? 2009 Expert Reviews Ltd.
Abstract
Rodent-borne hantaviruses are associated with two main clinical disorders in humans: hemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome. Although hantavirus diseases can be life threatening and numerous research efforts are focused on the development of hantavirus prevention, no specific antiviral therapy is yet available and, at this time, no WHO-approved vaccine has gained widespread acceptance. This review will summarize the current knowledge and recent progress as well as new speculative approaches in the development of hantavirus vaccines.
. . . .
Until now, there is no WHO-approved hantavirus vaccine available. However, at least three different inactivated vaccines, based on purified suckling-mouse brains, golden hamster kidney cells or Mongolian gerbil kidney cells, were developed in Korea and/or China, and which are being used only locally. A variety of vaccine approaches, however, have been investigated using both inactivated virus and recombinant DNA technology. These approaches will be further discussed later in this review.
http://www.medscape.com/viewarticle/586233
full article requires access to Medscape